Listen: Shocking FDA rejections, a setback in longevity science, & the latest on Covid-19 immunity
Did the FDA suddenly get stringent about new drugs? Is longevity research over-hyped? And what can recovered patients teach us about Covid-19 vaccines?
We discuss all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. First, we break down a pair of shocking FDA rejections for Gilead Sciences and BioMarin Pharmaceutical and what they might portend. Next, STAT’s Matthew Herper joins us to explain some disappointing results for Unity Biotechnology and the implications for longevity research. Finally, medicinal chemist and blogger Derek Lowe calls in to discuss the latest research on coronavirus immunity and the development of vaccines for Covid-19.
